Time-to-retraction and likelihood of evidence contamination (VITALITY Extension I): a retrospective cohort analysis
Yuan, Y.; Peng, Z.; Doi, S. A. R.; Furuya-Kanamori, L.; Cao, H.; Lin, L.; Chu, H.; Loke, Y.; Mol, B. W.; Golder, S.; Vohra, S.; Xu, C.
Show abstract
BackgroundThe number of problematic randomized clinical trials (RCTs) has risen sharply in recent decades, posing serious challenges to the integrity of the healthcare evidence ecosystem. ObjectiveTo investigate whether retraction of problematic RCTs could reduce evidence contamination. DesignRetrospective cohort study SettingA secondary analysis of the VITALITY Study database. Participants1,330 retracted RCTs with 847 systematic reviews. MeasurementsThe difference in the median number (and its interquartile, IQR) of contamination before and after retraction. The association between time-to-retraction and likelihood of evidence contamination. ResultsAmong these retracted RCTs, 426 led to evidence contamination, resulting in 1,106 contamination events (251 after retraction vs. 855 before retraction). The time interval between RCT publication and first contamination ranged from 0.2 to 30.9 years, with a median of 3.3 years (95% CI: 3.0 to 3.9). The median number of contaminated systematic reviews was lower after retraction than before retraction (0, IQR: 0 to 1 vs. 1, IQR: 1 to 2, P < 0.01). Compared with trials retracted more than 7.5 years after publication, those retracted between 1.0 and 1.8 years (OR = 0.70, 95% CI: 0.60 to 0.80) and retracted within 1.0 year (OR = 0.69, 95% CI: 0.60 to 0.80) were associated with lower likelihood of evidence contamination. LimitationsOnly assessed contaminated systematic reviews with quantitative synthesis and limited to retracted RCTs. ConclusionsRetracting problematic RCTs can significantly reduce evidence contamination, and faster retraction was associated with less contamination. To safeguard the integrity of the evidence ecosystem, academic journals should act promptly in the retraction of problematic studies to minimize their downstream impact. Primary Funding SourcesThe National Natural Science Foundation of China (72204003, 72574229)
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The impact of retracted randomised controlled trials on systematic reviews and clinical practice guidelines: a meta-epidemiological study 96%
- The use of the Registered Reports format for publication of randomized clinical trials: a cross-sectional study 96%
- Results dissemination from clinical trials conducted at German university medical centres was delayed and incomplete 96%
Similar papers in this journal
- Evaluation of the sensitivity, accuracy and currency of the Cochrane COVID-19 Study Register for supporting rapid evidence synthesis production 97%
- Synthesizing evidence from the earliest studies to support decision-making: to what extent could the evidence be reliable? 97%
- Exploring the potential of Claude 2 for risk of bias assessment: Using a large language model to assess randomized controlled trials with RoB 2 96%
Similar papers in this journal
- Investigator-initiated versus industry-sponsored trials – Visibility and relevance of randomized controlled trials in clinical practice guidelines (IMPACT) 96%
- Does pre-notification increase questionnaire response rates: a nested randomised control trial 94%
- Does advance contact with research participants increase response to questionnaires: A Systematic Review and meta-Analysis 94%
Similar papers in this journal
- Exploring scalable assessment methods for terminated trials in ClinicalTrials.gov: A cohort analysis of German and Californian trials 95%
- How Informative Were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov 94%
- Modelling the impact of behavioural interventions during pandemics: A systematic review 93%
Similar papers in this journal
- Transparency and reporting characteristics of COVID-19 randomized controlled trials 98%
- Tool to assess risk of bias due to missing evidence in network meta-analysis (ROB-MEN): elaboration and examples 95%
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.